Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, explains how the new US stance could change the TRIPS waiver debate.
New data explores why some in the UK continue to experience vaccine hesitancy - with one man explaining that "it is human nature to have second thoughts".
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that all under 40s should be offered an alternative to the Oxford/AstraZeneca vaccine following blood clot risk.
The European Commission on Thursday (6 May) responded to a US declaration of support for the TRIPS waiver, stating that they were open to further discussions without explicit agreement.
The CureVac mRNA vaccine is currently in final stages of clinical trials - but it is expected to perform like Pfizer and Moderna, with the bonus of surviving at ordinary refrigeration temperatures.
A new study has revealed that new medicines and vaccines approved for use in the United States are often unavailable in countries that helped to develop them.
The TRIPS waiver would temporarily stop an intellectual property law that stops poorer countries to manufacture the vaccine - the US now joins India and South Africa in the proposal.
A patient with vaccine-inducted thrombotic thrombocytopenia was successfully treated with a heparin alternative, after receiving the Johnson & Johnson vaccine.
A study by Annenberg Public Policy Center (APPC) researchers has found that users of conservative and social media are more likely to believe COVID-19 conspiracy theories.
A new study has found that a single dose of the COVID-19 vaccine boosts protection against SARS-CoV-2 variants, but only in those with previous infection.
Pfizer could make their COVID vaccine available to 12-year-olds in Europe from June, after clinical trials in March showed 100% efficiency for those aged 12 to 15.
